Ozempic, Wegovy face US Medicare price negotiations

Novo Suffers Wegovy Trial Setback as US Plans to Cut Price
Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks
GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief.
Ozempic and Wegovy among drugs on Medicare list getting price cuts
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.
Wegovy, Ozempic targeted for Medicare price negotiations
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.
Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.
Ozempic, Wegovy are among 15 drugs selected for Medicare’s price negotiations
U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.
Ozempic among drugs targeted in upcoming Medicare price negotiations
Novo Nordisk’s blockbuster diabetes and weight-loss drugs Ozempic and Wegovy are among a group of 15 drugs set to be affected by the next round of US government price negotiations by Medicare. The group of drugs accounted for about $41bn in annual spending by Medicare,
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

High-dose Wegovy leads to substantial weight loss in trial

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, Cloudflare, and More
Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...
LVMH Reclaims Title of Europe’s Most Valuable Stock From Novo
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Novo Nordisk, other companies to meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...
Zealand Seeks to Usurp Wegovy, Zepbound With Obesity Drug
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...